Old Web
English
Sign In
Acemap
>
Paper
>
OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC
OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC
2021
Taofeek K. Owonikoko
Michael Boyer
Melissa Lynne Johnson
Ramaswamy Govindan
L. Rodrigues
Fiona H Blackhall
R.J. Boosman
Stéphane Champiat
H. Hummel
Wei-Chu Victoria Lai
Hibiki Udagawa
Anne C. Chiang
Afshin Dowlati
Christine L. Hann
Ravi Salgia
E. E. Vokes
M Minocha
N Sadraei
A Shetty
Marie-Anne Damiette Smit
Ying Zhang
B. Sable
A. Pati
S. Roy
Hossein Borghaei
Keywords:
Medicine
immune therapy
Cancer research
Half-life
T cell
Phase (matter)
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]